United States

Report: Midwest healthcare companies raise $1.8B in 2014

Wednesday, January 21, 2015 01:06 PM

Midwest healthcare companies attracted $1.8 billion in new investments across 243 companies in 2014, according to the BioEnterprise Midwest Healthcare Growth Capital Report. The totals are the highest recorded in both dollars and number of companies funded since BioEnterprise began compiling the report in 2005, surpassing the banner 2007 by 46% and 2013 by 135%. BioEnterprise is a business formation, recruitment, and acceleration initiative designed to grow healthcare companies and commercialize bioscience technologies based in Cleveland, Ohio.

More... »


FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »


TapImmune reports positive immune responses in phase I cancer trial

Friday, January 16, 2015 01:08 PM

TapImmune, an immunotherapy company, has reported the completion of data analysis from all 21 evaluable patients treated in a phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into phase II trials.

More... »

FDA approves VBLOC vagal blocking therapy for obesity

Friday, January 16, 2015 12:52 PM

The FDA has approved medical device company EnteroMedics’ VBLOC vagal blocking therapy, delivered via the Maestro System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years.

More... »

35 partners from industry and academia collaborate on European research initiative

Thursday, January 15, 2015 01:40 PM

The European Prevention of Alzheimer's Dementia (EPAD) initiative has begun a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.

More... »

Crohn's & Colitis Foundation of America, ResearchMatch partner

Wednesday, January 14, 2015 12:32 PM

ResearchMatch, a U.S.-wide, disease-neutral, volunteer research recruitment and engagement platform, is partnering with the Crohn's & Colitis Foundation of America (CCFA), a volunteer-driven organization dedicated to curing Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by those diseases.

More... »

goBalto releases latest update of goBalto Activate

Wednesday, January 14, 2015 12:32 PM

goBalto, a San Francisco, Calif.-based provider of cloud-based clinical study startup solutions, has released its latest version of goBalto Activate, its flagship study startup platform.

More... »

Novella Clinical, Cardiovascular Research Foundation collaborate, provide clinical trial expertise

Monday, January 12, 2015 02:37 PM

Novella Clinical, a Quintiles company, and the Cardiovascular Research Foundation (CRF), an independent, academically focused nonprofit organization based in New York, have announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices.

More... »

MedNet Solutions updates iMedNet eClinical

Friday, January 9, 2015 02:03 PM

MedNet Solutions, a Minnetonka, Minn.-based global life sciences technology company specializing in clinical study management systems, has updated iMedNet eClinical, its innovative, cloud-based technology platform. iMedNet said its software-as-a-service (SaaS) solution is intuitive, flexible and affordable for sponsors and CROs wishing to quickly and efficiently build studies themselves.

More... »

Inovio Pharmaceuticals HIV immunotherapy shows vital characteristics

Thursday, January 8, 2015 02:28 PM

Inovio Pharmaceuticals has reported results from a 12-patient, phase I study of Inovio's HIV immunotherapy, PENNVAX-B, in HIV-infected patients revealed that immune response characteristics generated by the immunotherapy were similar to those observed in HIV-infected individuals who without treatment do not progress to further stages of the disease.

More... »

`

CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs